Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.

Nuvaira, a US-based developer of treatments for obstructive lung diseases, closed a $79m series E round on Monday led by venture capital firm US Venture Partners. The round also featured venture capital firms Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, Advanced Technology Ventures (ATV), Split Rock Partners and Windham Venture Partners as well as philanthropic…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.